Flurry of Bullish Inflows Sends United Therapeutics Higher

UTHR is a biotechnology company that develops and sells treatments for chronic and life-threatening conditions, with products including Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company’s third-quarter fiscal 2025 earnings report showed $800 million in revenue (a 7% year-over-year jump), increased market share on several products, progressing clinical trials, as well as guidance of up to $4 billion in revenue by 2027.

It’s no wonder UTHR shares are up 34% this year, and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock.

United Therapeutics Draws Big Money

Institutional volumes reveal plenty. In the last year, UTHR has endured some choppiness. But it’s once again enjoying strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in UTHR shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with United Therapeutics.

United Therapeutics Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, UTHR has had strong sales and earnings growth:

• 3-year sales growth rate (+19.6%)
• 3-year EPS growth rate (+36%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +10.4%.

Now it makes sense why the stock has been generating Big Money interest. UTHR has a track record of strong financial performance.

Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term.

United Therapeutics has been a top-rated stock at MoneyFlows for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

In the last 20 years, UTHR has drawn many outlier inflow signals and is up 824% since the one in November 2007. The blue bars below show when UTHR was a top pick on the Outlier 20 report…it’s clearly a Big Money favorite:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

United Therapeutics Price Prediction

The UTHR action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in UTHR at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level and follow our free weekly MoneyFlows insights.